Novo Nordisk A/S NVO has encountered manufacturing challenges and drug shortages for its diabetes and weight loss drugs due to unprecedented demand for Wegvoy and Ozempic. To manage the shortage, Novo Nordisk agreed to…
Eli Lilly And Co’s LLY shares are trading higher with a session volume of 1.683 million versus an average volume of 3.12 million, according to data from Benzinga Pro. However, there is…
Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk NVO, and it’s something market players shouldn’t ignore. Our tracking of public options records at Benzinga unveiled this significant move…
What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors…
A clinical trial has revealed that Novo Nordisk’s NVO weight loss drug Wegovy significantly decreases the risk of serious heart complications. According to CNBC, the Select study tested Wegovy on…